Chen Bin, Pogue Brian W, Goodwin Isak A, O'Hara Julia A, Wilmot Carmen M, Hutchins John E, Hoopes P Jack, Hasan Tayyaba
Thayer School of Engineering, Dartmouth College, Hanover, New Hampshire 03755, USA.
Radiat Res. 2003 Oct;160(4):452-9. doi: 10.1667/RR3059.
In the present study, the effects of photodynamic therapy (PDT) with verteporfin on tumor blood flow and tumor regrowth were compared as verteporfin distributed in different compartments within the RIF-1 tumor. Tissue distribution of verteporfin was examined by fluorescence microscopy, and blood flow measurements were taken with a laser Doppler system. It was found that, at 15 min after drug administration, when verteporfin was mainly confined within the vasculature, PDT induced a complete arrest of blood flow by 6 h after treatment. PDT treatment at a longer drug-light interval (3 h), which allowed the drug to diffuse to the tumor interstitium, caused significantly less flow decrease, only to 50% of the initial flow in 6 h. A histological study and Hoechst 33342 staining of functional tumor vasculature confirmed the primary vascular damage and the decrease in tumor perfusion. The regrowth rate of tumors treated with 15-min interval PDT was 64% of that of the control group. However, when tumors were treated with 3-h interval PDT, the regrowth rate was not significantly different from that of the control, indicating that only the 15-min interval PDT caused serious damage to the tumor vascular bed. These results support the hypothesis that temporal pharmacokinetic changes in the distribution of the photosensitizer between the tumor parenchyma and blood vessels can significantly alter the tumor target of PDT.
在本研究中,比较了维替泊芬光动力疗法(PDT)对肿瘤血流和肿瘤再生长的影响,因为维替泊芬在RIF-1肿瘤的不同区域分布。通过荧光显微镜检查维替泊芬的组织分布,并用激光多普勒系统进行血流测量。结果发现,给药后15分钟,当维替泊芬主要局限于脉管系统时,PDT在治疗后6小时可使血流完全停止。在较长的药物-光照间隔(3小时)下进行PDT治疗,使药物扩散到肿瘤间质,导致血流减少明显较少,6小时内仅降至初始血流的50%。对功能性肿瘤脉管系统的组织学研究和Hoechst 33342染色证实了主要的血管损伤和肿瘤灌注的降低。间隔15分钟进行PDT治疗的肿瘤再生长率为对照组的64%。然而,当肿瘤采用间隔3小时的PDT治疗时,其再生长率与对照组无显著差异,表明只有间隔15分钟的PDT对肿瘤血管床造成了严重损伤。这些结果支持以下假设:光敏剂在肿瘤实质和血管之间分布的时间性药代动力学变化可显著改变PDT的肿瘤靶点。